Ignite Creation Date:
2024-05-06 @ 8:28 AM
Last Modification Date:
2024-10-26 @ 12:00 PM
Study NCT ID:
NCT02747472
Status:
COMPLETED
Last Update Posted:
2017-04-27
First Post:
2016-04-19
Brief Title:
GIP Receptor Antagonist Studies in Humans
Sponsor:
University Hospital Gentofte Copenhagen
Organization:
University Hospital Gentofte Copenhagen
Study Overview
Official Title:
Involvement of Glucose-dependent Insulinotropic Polypeptide GIP in Human Physiology and Pathophysiology - Receptor Antagonist Studies in Humans
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GA-1
Brief Summary:
Antagonizing GIP effects during hyperglycaemia in healthy subjects and measurements of insulin secretion
Detailed Description:
Aim To evaluate the GIP receptor antagonizing effect of peptide-based competitive GIP receptor antagonist GIP-A vs saline placebo in 10 healthy subjects during 1 hour hyperglycaemic clamps with and without concomitant iv infusion of GIP1-42 The intention is to establish GIP-A as a tool to eliminate glucose-dependent insulinotropic GIP signalling
The study consists of four experimental days A-D with assessment of beta cell function during 12 mM-hyperglycaemic clamps with concomitant infusions of A GIP1-42 B GIP-A C GIP1-42 GIP-A or D saline placebo
The study consists of four experimental days A-D with assessment of beta cell function during 12 mM-hyperglycaemic clamps with concomitant infusions of A GIP1-42 B GIP-A C GIP1-42 GIP-A or D saline placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None